Analysts Set Bicara Therapeutics Inc. (NASDAQ:BCAX) PT at $43.33

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $43.00.

Several equities research analysts recently commented on BCAX shares. Morgan Stanley assumed coverage on Bicara Therapeutics in a report on Tuesday, October 8th. They issued an “overweight” rating and a $35.00 price objective for the company. Cantor Fitzgerald initiated coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They issued an “overweight” rating for the company. Stifel Nicolaus began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective on the stock. TD Cowen began coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, Rodman & Renshaw assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They set a “buy” rating and a $48.00 target price for the company.

Bicara Therapeutics Stock Up 8.0 %

Shares of BCAX opened at $21.10 on Friday. Bicara Therapeutics has a twelve month low of $17.41 and a twelve month high of $28.09. The firm’s 50 day moving average price is $21.73.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, sell-side analysts anticipate that Bicara Therapeutics will post -2.89 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the business’s stock in a transaction on Monday, September 16th. The stock was acquired at an average price of $18.00 per share, with a total value of $32,994,000.00. Following the completion of the acquisition, the director now owns 4,303,418 shares of the company’s stock, valued at approximately $77,461,524. This trade represents a 74.20 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, major shareholder James E. Flynn acquired 70,000 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the purchase, the insider now directly owns 897,587 shares of the company’s stock, valued at approximately $16,156,566. This trade represents a 8.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Cinctive Capital Management LP purchased a new position in Bicara Therapeutics during the third quarter valued at approximately $229,000. Barclays PLC bought a new stake in shares of Bicara Therapeutics during the 3rd quarter valued at $255,000. Jane Street Group LLC purchased a new position in shares of Bicara Therapeutics during the 3rd quarter valued at $309,000. Teachers Retirement System of The State of Kentucky bought a new position in Bicara Therapeutics in the 3rd quarter worth $358,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Bicara Therapeutics in the 3rd quarter worth $462,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.